Drug, bio-affecting and body treating compositions inventions 12/07

20070299017 - Compositions for lowering blood serum cholesterol and use in foods, beverages, and health supplements: There is disclosed a composition comprising at least one of a compound selected from the group consisting of a bioflavonoid, a beta-1,3-beta-1,4-polymer of glucose having a weight average molecular weight (MW) of not greater than 1000 kDa, and a sterol. Moreover, there is disclosed a food or beverage or health... Agent: Cargill, Incorporated

20070298998 - Biomarkers for amyotrophic lateral sclerosis and methods using the same: The present invention provides various biomarkers of amyotrophic lateral sclerosis (ALS). The present invention also provides various methods of using the biomarkers, including methods for diagnosis of ALS, methods of determining predisposition to ALS, methods of monitoring progression/regression of ALS, methods of assessing efficacy of compositions for treating ALS, methods... Agent: Hutchison Law Group PLLC

20070298997 - Compounds useful in treating diabetic microvascular complications and age-related macular degeneration: The present invention is directed to a method of treating microvascular complications associated with diabetes and age-related macular degeneration. The methods include administering to an animal in need thereof an effective amount of a composition, wherein the composition is selected from the group consisting of kallistatin, fragments of kallistatin, analogs... Agent: Dunlap Codding & Rogers, P.C.

20070298999 - Method for treating pain with a calmodulin inhibitor: The present invention relates to the use of Ca2+/CaM-dependent protein kinase II (CaMKII) inhibitors alone and in combination with opiate analgesics for treating pain, in particular chronic pain. Methods for reducing or reversing tolerance and dependence on opiate analgesics are also provides.... Agent: Jane Massey Licata Licata & Tyrrell P.C.

20070299000 - Method of lowering body fat percentage or inhibiting body fat percentage increase: A body fat percentage-lowering agent or an inhibitor for an increase in body fat percentage containing soybean 7S protein as the active ingredient and foods containing the same. As the soybean protein 7S protein, use is made of a protein the purity of which is elevated by sufficiently separating from... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070298996 - Methods of using chimeric coiled-coil molecule: The present application discloses a method of treating a disease that is treatable by therapeutic angiogenesis comprising administering to a needy subject an effective amount of a chimeric coiled coil molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand.... Agent: Jhk Law

20070299001 - Purified hcg: A process for the purification of recombinant human Chorionic Gonadotropin (hCG) from a sample of crude recombinant hCG in the supernatant of CHO cells comprises the combined use of ion-exchange chromatography and reverse phase HPLC. The ion-exchange chromatography is performed twice and the final use of a size exclusion chromatography... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070299002 - Alpha1-acid glycoprotein for the treatment of diabetes: Methods of using alpha-1-acid glycoprotein, or an active derivative, to modulate the blood glucose level in mammals, particularly humans, is described. A therapeutically effective amount of alpha-1-acid glycoprotein is administered to a patient afflicted with Type 1 or Type 2 diabetes to lower the blood glucose level. An anti-diabetic medicament,... Agent: Faegre & Benson LLP Patent Docketing

20070299003 - Composition comprising a pulmonary surfactant and a tnf-derived peptide: The invention relates to the combination of a pulmonary surfactant and a TNF-derived peptide and its use for the treatment of respiratory disease.... Agent: Nath & Associates PLLC

20070299004 - Methods of providing therapeutic effects using cyclosporin compontnts: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the... Agent: Stout, Uxa, Buyan & Mullins LLP

20070299009 - Analogs of parathyroid hormone: The present invention is directed to peptide analogues of fragment of parathyroid hormone (PTH) or parathyroid hormone-related protein (PTHrP), a method of using said analogues alone or in combination with a bisphosphonate or calcitonin to treat osteoporosis and pharmaceutical compositions comprising said analogues alone or in combination with a bisphosphonate... Agent: Biomeasure, Incorporated

20070299011 - Appoptosin and uses thereof for treating neurodegenerative disease and cancer: Disclosed herein are compositions and methods relating to the modulation of Appoptosin levels or activity in the treatment of Neurodegenerative disorders or cancer.... Agent: Needle & Rosenberg, P.C.

20070299010 - Cpg15 and cpg15-2 compounds and inhibitors as insulin receptor and insulin-like growth factor receptor agonists and antagonists: Disclosed herein are CPG15 and CPG15-2 compounds and inhibitors that act as agonists and antagonists of the insulin receptor and insulin-like growth factor receptors, and the use of such compositions for the treatment of insulin and insulin-like growth factor-related diseases.... Agent: Clark & Elbing LLP

20070299005 - Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof: An isolated polynucleotide at least 60% homologous to SEQ ID NO: 1, 3, 5 or 18 encoding a SARP polypeptide; vectors comprising a polynucleotide sequence encoding at least 11 consecutive amino acids of αSARP polypeptide; a host cell transformed with an isolated polynucleotide or vector; antibodies specific for SARP and... Agent: Sheridan Ross PC

20070299007 - Muteins of fibroblast growth factor 21: The present invention relates to novel muteins of human fibroblast growth factor-21 with reduced susceptibility for proteolytic degradation when expressed in yeast. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and... Agent: Eli Lilly & Company

20070299006 - Recombinant fusion proteins to growth hormone and serum albumin: The invention describes albumin fusion proteins comprising growth hormone and serum albumin. The invention also describes nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acid molecules, host cells transformed with these vectors, and methods of making the albumin fusion proteins... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070299008 - Transport protein which is used to introduce chemical compounds into nerve cells: The invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum. The protein binds specifically to nerve cells with a higher affinity as the native neurotoxin. The invention also relates to a method for the production of transport... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070299012 - Method of preventing progression of hypertension-induced heart failure with pkc peptides: Methods are described for slowing or inhibiting the progression of heart failure in a mammalian subject suffering from chronic hypertension. The methods involve administering an εPKC, β1PKC, or βIIPKC peptide inhibitor, examples of which are provided.... Agent: Perkins Coie LLP

20070299013 - Exosite-directed thrombin inhibitors: Disclosed are an amino acid sequence of the human blood clotting factor Va, peptides containing such sequence, and additional peptides of interest that significantly inhibit thrombin generation. Also disclosed are pharmaceutical compositions containing these peptides and related therapeutic methods for inhibiting thrombin generation and treating blood coagulation disorders.... Agent: Mark E Bandy Fay Sharpe Fagan Minnich & Mckee LLP

20070299014 - Casein hydrolyzate, process for producing the same and use thereof: The present invention relates to a casein hydrolysate containing free amino acids and in vivo indigestible peptides having minimally suppressed in vivo enzymatic digestibility, and expected to express functions, such as hypotensive effect, in living organism, and to a method for preparing such a hydrolysate, and use thereof. The casein... Agent: Darby & Darby P.C.

20070299015 - Peptide fragments for inducing synthesis of extracellular matrix proteins: Short biologically active tetrapeptides are disclosed that are comprised of the sequences GxxG and PxxP where G (glycine) and P (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extracellular matrix proteins in skin. A rapid,... Agent: Howrey LLP

20070299016 - Specific antibodies for diagnosing heart failure: The invention relates to an in vitro diagnosis of heart failure. More specifically, the invention relates to specific antibodies of a peptide domain which is situated on either side of hinge region R76S77 of proBNP(1-108). In particular, the invention relates to a method of obtaining the aforementioned antibodies and to... Agent: Jacobson Holman PLLC

20070299018 - Derivatives of genkwanin and sakuranetin, cosmetic and therapeutic use thereof and preparation method of same: The invention relates to: (i) the use of osyl derivatives of genkwanin and sakuranetin having formula (I) in (a) cosmetics or dermatology and (b) therapeutics; (ii) the use of novel derivatives having formula (I) as industrial products; and (iii) the production method thereof [Formula (I)], wherein symbol [Formula (II)] represents... Agent: Ostrolenk Faber Gerb & Soffen

20070299019 - Macrolides and methods for producing same: This invention relates, in part, to macrolide compounds, actinomycete strains for producing them, and pharmaceutical compositions containing them.... Agent: Howson And Howson/wyeth Cathy A. Kodroff

20070299020 - Methods for treatment of ovarian, colorectal or pancreatic cancer using 4-(aminno)-2(2,6-dioxo(3-piperidyl)-isoindoline-1,3-dione: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or... Agent: Jones Day

20070299022 - Antisense oligonucleotide to inhibit melanoma inhibitory activity mia: An antisense oligonucleotide selected from the group of the sequence 5′-TTG CAT AAA CCC AAG GAG-3′ and modifications thereof a fragment having at least 8 nucleotides of the sequence 5′-TTG CAT AAA CCC AAG GAG-3′ and modifications thereof.... Agent: Wood, Herron & Evans, LLP

20070299028 - Backbone modifications to modulate oligonucleotide targeting in vivo: The present invention provides antisense compounds and methods for modulating the expression of target genes expressed in the kidney. In particular, this invention provides antisense oligonucleotide compounds optimized for targeting nucleic acid molecules expressed in the kidney. Such compounds are shown herein to efficiently modulate the expression of target genes... Agent: Mcdermott Will & Emery

20070299024 - Cloning and characterization of 5'flanking regions of a human aggrecanase-1 gene: Disclosed is a nucleic acid comprising Agg promoters and methods of using the same. The invention also provides methods for identifying and treating disease based on the activity of Agg promoters.... Agent: Novartis Corporate Intellectual Property

20070299027 - Compositions and their uses directed to huntingtin: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease... Agent: Knobbe, Martens, Olson & Bear, LLP

20070299029 - Hepatic stellate cell specific promoter and uses thereof: Methods and reagents for effecting transgene expression in a hepatic stellate cell, isolated transgenic hepatic stellate cells, methods and reagents for identifying compounds with fibrogenesis modulating properties and uses thereof.... Agent: Klarquist Sparkman, LLP

20070299026 - Immunosuppressive cytokine: The EB1-3-p35 cytokine is shown for the first time to be capable of inhibiting immune responses mediated or controlled by T cells via an effect on suppressor T cells. This suggests that EBI3-p35 may be therapeutically effective in a variety of inflammatory and autoimmune conditions including arthritis, atherosclerosis, allograft rejection,... Agent: Dann, Dorfman, Herrell & Skillman

20070299025 - Method for detecting the risk of cardiovascular diseases such as acute myocardial infarction and coronary heart disease by analysing defesin: The invention provides a method of identifying subject's susceptibility or predisposition to or risk of developing cardiovascular diseases such as myocardial infarction (MI) or coronary heart disease (CHD) by detecting gene polymorphisms and other gene mutations in a defensin gene from a biological sample of the subject and obtaining information... Agent: Birch Stewart Kolasch & Birch

20070299030 - Microrna biomarkers for human breast and lung cancer: The present invention relates to novel molecular markers for diagnosis and classification of human breast cancer and lung cancer.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070299021 - Modified tailed oligonucleotides: A nucleic acid molecule comprising first and second domains, said first domain being capable of forming a first specific binding pair with a target sequence of a target RNA species, said second domain consisting of a sequence which forms a second specific binding pair with at least one RNA processing... Agent: Jaeckle Fleischmann & Mugel, LLP

20070299023 - P185neu-encoding dna and therapeutical uses thereof: Plasmids containing sequences encoding different fragments of p185neu oncoprotein, able to induce an immune response against tumours expressing oncogenes of the ErbB family, and pharmaceutical compositions thereof.... Agent: Young & Thompson

20070299031 - Therapeutic agent for tumor of neural origin: The present invention is directed to a therapeutic agent for a tumor of neural origin, containing, as an active ingredient, any of the following: Hu protein; a polypeptide having an amino acid sequence derived from an amino acid sequence of Hu protein by substitution, deletion, addition, or insertion of one... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070299032 - Method and composition for thickening hair: The present invention provides a method for maintaining and promoting hair thickening by increasing the expression of keratinocyte growth factor (FGF-7) in hair follicle cells, and preferably dermal papilla cells, a composition for increasing expression of FGF-7 that contains adenosine and/or a derivative thereof, and particularly, an external scalp preparation... Agent: Snider & Associates

20070299033 - Pharmaceutical co-crystal compositions and related methods of use: The present invention comprises pharmaceutical compositions comprising a co-crystal of an API and a co-crystal former, and methods of making and using the same.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070299034 - Cell wall derivatives, their preparation process, and use thereof: In a first aspect, the present invention relates to a method for isolating cell wall derivatives from fungal or yeast biomass. According to this method, chitin polymers or chitin-glucan copolymers can be obtained. In another aspect, the invention relates to a method for preparing chitosan from chitin. The invention further... Agent: Clark & Brody

20070299035 - Use of chemical chelators as reversal agents for drug-induced neuromuscular block:

20070299036 - Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-iv: The present invention is directed to a method of treatment of a malcondition that can be regulated or normalized via inhibition of DPP-IV. The method involves administration of an effective amount of a pyrrolidine compound of the invention, such as would be present in a pharmaceutical composition of the invention,... Agent: Schwegman, Lundberg & Woessner, P.A.

20070299037 - Synergistic and residual pesticidal compositions containing plant essential oils: Synergistic and residual pesticidal compositions containing synergistic and residual mixtures of plant essential oils and/or their constituents, plant essential oils and/or their constituents in admixture with known active pesticidal compounds or plant essential oils and/or their constituents in admixture with other compounds not previously used as active ingredients in pesticidal... Agent: Nixon & Vanderhye, PC

20070299038 - Synergistic and residual pesticidal compositions containing plant essential oils: Synergistic and residual pesticidal compositions containing synergistic and residual mixtures of plant essential oils and/or their constituents, plant essential oils and/or their constituents in admixture with known active pesticidal compounds or plant essential oils and/or their constituents in admixture with other compounds not previously used as active ingredients in pesticidal... Agent: Nixon & Vanderhye, PC

20070299039 - Substituted benz-azoles and methods of their use as inhibitors of raf kinase: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as... Agent: Chiron Corporation Intellectual Property - R440

20070299040 - Composition for preventing a cold: The present invention relates a composition for preventing cold comprising vitamin C and ginkgetin, a use of the composition for preparing a medicine To prevent cold, a method for preventing cold by using the composition, and method for preparing cold prophylactic. The composition of the present invention has excellent inhibition... Agent: Ipla P.A.

20070299041 - Induction of innate immunity by vitamin d3 and its analogs: Cationic antimicrobial peptides (AMPs) are an integral part of the innate immune system. Cathelicidin and defensin homologs from a variety of species exhibit broad-range bactericidal activity. The human cathelicidin analog, hCAP18, is encoded by the CAMP gene. Vitamin D3 and its analogs upregulate transcription of CAMP and defensin B2 (defB2)... Agent: Davis Wright Tremaine LLP/los Angeles

20070299043 - Anti-scarring drug combinations and use thereof: The present invention provides devices or implants that comprise anti-scarring drug combinations, methods or making such devices or implants, and methods of inhibiting fibrosis between the devices or implants and tissue surrounding the devices or implants. The present invention also provides compositions that comprise anti-fibrotic drug combinations, and their uses... Agent: Clark & Elbing LLP

20070299042 - Use of etodolac to treat hyperplasia: wherein R1 is lower alkyl, (hydroxy)lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, phenyl, benzyl or 2-thienyl; R2, R3, R4 and R5 are the same or different and are each hydrogen or lower alkyl; each R6 is individually hydrogen, lower alkyl, hydroxy, (hydroxy)lower alkyl, lower alkoxy, benzyloxy, lower alkanoyloxy, nitro... Agent: Schwegman, Lundberg & Woessner, P.A.

20070299044 - Corticosteroid topical dispersion with low content of surfactant: The invention provides novel compositions of water-insoluble corticosteroid drug in combination with antimicrobial agents and very low concentrations of polymers and surfactants for topical, otic and ophthalmic treatment. The invention provides stable aqueous suspension where the ingredients remain in such a state so as to allow for immediate re-suspension, when... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070299045 - Anti-viral composition for the topical treatment of herpes labialis (cold sores) and method for use thereof: A composition for the treatment of Herpes Labialis which contains CTC-96 as the active ingredient is disclosed. Methods for using the composition are also disclosed. The composition may be used as a topical ointment.... Agent: Reed Smith, LLP Attn: Patent Records Department

20070299046 - Orally available light-independent antineoplastic compounds: Pheophorbide derivative compounds which can inhibit cell proliferation and angiogenesis in a light-independent manner are disclosed and claimed. Importantly, these compounds exhibit low toxicity, and are orally/subcutaneous/intravenously/transdermally/topically available, thus having value as new potential agents to treat cancer or diseases related to imbalance in cell proliferation and angiogenesis.... Agent: Craig A. Crandall, Apc

20070299047 - Combination of organic compounds: The present invention relates to a pharmaceutical composition, comprising a PPAR agonist, or pharmaceutically acceptable salts thereof, alone or in combination with at least one active ingredient selected from the group consisting of (i) HDL increasing compounds; (ii) anti-diabetics; (iii) an anti-hypertensive agent; (iv) cholesterol absorption modulator; (v) apo-A1 analogs... Agent: Novartis Corporate Intellectual Property

20070299048 - Combination of gaboxadol and 5ht2 antagonists: The invention provides the combination of a 5-HT2A antagonist and gaboxadol for use in treatment or prevention of sleep disorders, schizophrenia or depression.... Agent: Merck And Co., Inc

20070299049 - Pharmaceutical uses of staurosporine derivatives: This application relates to the use of staurosporines derivatives for the curative, palliative or prophylactic treatment of allergic rhinitis, allergic dermatitis, drug allergy or food allergy, angioedema, urticaria, sudden infant death syndrome, bronchopulmonary aspergillosis, multiple sclerosis, or mastocytosis; and to a method of treatment of warm-blooded animals in which a... Agent: Novartis Corporate Intellectual Property

20070299050 - Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha: are disclosed, wherein V is CH2; W is S(O)m; m is the integer 0, 1 or 2; U is O, C(O), CR13R14 or NR15; where R13 is H, alkyl; R14 is H, OH, OR13 or OCOR13; R15 is H, alkyl, cycloalkyl, alkenyl, C(O)R13, C(O)OR13 or alkylaminocarbonyl; R1, R2, R3, R4,... Agent: Merchant & Gould PC

20070299051 - Tricyclic guanidine derivatives as sodium-proton exchange inhibitors: are disclosed, wherein U is C(O), CRaRb, O, NRa or S(O)m; V is CRaRb or NRa; W is S(O)m; wherein Ra is H, alkyl, cycloalkyl, alkenyl or aralkyl; Rb is H, alkyl, OH, ORa or OCORa, and m is the integer 0, 1 or 2; R1, R2, R3, R4, R5,... Agent: Merchant & Gould PC

20070299052 - Inhibitors of iap: e

20070299054 - Oral pharmaceutical composition of a poorly water-soluble active agent: The present invention relates to an improved oral pharmaceutical composition containing at least one poorly water soluble active agent, the active agent containing at least one of an endothelin conversion enzyme (ECE) inhibitor and a neutral endopeptidase (NEP) inhibitor in an amount greater than 10% w/w of the composition, and... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070299053 - Lactam compound: The present invention provides crystalline (N)-((S)-2-hydroxy-3-methyl-butyryl)-1-(L-alaninyl)-(S)-1-amino-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one, a crystalline anydrate and dihydrates thereof, compositions comprising (N)-((S)-2-hydroxy-3-methyl-butyryl)-1-(L-alaninyl)-(S)-1-amino-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one, its crystalline anhydrate or dihydrate, and methods for using the same.... Agent: Eli Lilly & Company

20070299055 - Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is... Agent: Heslin Rothenberg Farley & Mesiti P.C.

20070299056 - Benzazepine derivatives for the treatment of neurological disorders: The present invention relates to benzazepine derivatives of formula (I) wherein: R1 represents —C3-7 cycloalkyl optionally substituted by C1-3 alkyl; having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070299057 - Heterocyclic piperidines as modulators of chemokine receptor activity: e

20070299058 - Anxiolytic agents with reduced sedative and ataxic effects: Orally active benzodiazepine derivatives and their salts are disclosed. These compounds and their salts have anxiolytic and anticonvulsant activity with reduced sedative/hypnotic/muscle relaxant/ataxic effects.... Agent: Wisys Technology Foundation, Inc. C/o Mirick, O'connell, Demallie & Lougee, LLP

20070299059 - Compostions and methods relating to novel compounds and targets thereof: The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and methods of using benzodiazepine derivatives as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell... Agent: Casimir Jones, S.c.

20070299060 - Cycloalkyl substituted pyrimidinediamine compounds and their uses: The present disclosure provides 2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferate diseases such as tumorigenic cancers.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070299061 - Fused [d]pyridazin-7-ones: The present invention is directed to fused [d]pyridazin-7-ones. The invention is also directed to methods for making and using the fused [d]pyridazin-7-ones. In particular, the compounds of the present invention may be effective in the treatment of diseases or disease states related to the activity of VEGFR2, MLK1 and CDK5... Agent: Cephalon, Inc.

20070299062 - Melanin concentrating hormone antagonists: The present invention relates to compounds capable of serving as moderators of human and mammalian appetite and as such provide a means for reducing body mass and controlling obesity.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070299063 - N3 alkylated benzimidazole derivatives as mek inhibitors: and pharmaceutically acceptable salts thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in... Agent: Hogan & Hartson LLP

20070299064 - Pesticidal heterocyclic dihaloallyl compounds: Het, A1, A2, A3, A4, D, W, T, Q, Y, X1, X2, R1, R2, R3, R4, k and m are as defined hereinabove, and, where applicable, to possible E/Z isomers, mixtures of E/Z isomers and/or tautomers thereof, in each case in free form or in salt form, to a process... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20070299065 - Tetrahydropyran derivatives as antidiabetics: Novel compounds of the formula (I), in which T, E, R, R′, R″, R1, R2 and R2′ have the meanings indicated in patent Claim 1, are suitable as antidiabetics.... Agent: Millen, White, Zelano & Branigan, P.C.

20070299066 - Novel pyrimidothienoindazoles: v

20070299067 - Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors: The present invention is directed to certain quinoline and isoquinoline compounds that are PDE10 inhibitors, pharmaceutical compositions containing such compounds and processes for preparing such compounds. The invention is also directed to methods of treating diseases mediated by PDE10 enzyme, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive... Agent: Jones Day

20070299070 - 2-arylcarboxamide-nitrogenous heterocycle compound: [wherein R1 and R2 are the same or different and each represents C1-6 alkyl, C3-8 cycloalkyl, et al; R3a, R3b, and R4 are the same or different and each represents hydrogen, C1-6 alkyl, et al; X represents —N—, —CH—, et al; Y, represents a single bond, C1-3 alkylene, et al;... Agent: Merck And Co., Inc

20070299068 - Methods for treating hepatitis c: The present invention provides compounds, pharmaceutical compositions, and methods of using such compounds or compositions for treating infection by a virus, or for affecting viral IRES activity.... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20070299069 - Methods for treating hepatitis c: The present invention provides compounds, pharmaceutical compositions, and methods of using such compounds or compositions for treating infection by a virus, or for affecting viral IRES activity.... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20070299071 - Substituted phenyl methanone derivatives: e

20070299073 - Imidazolyl derivatives: The present invention is directed to imidazolyl derivatives of formula (I) where the substituents are defined in the specification, which are useful as agonist or antagonists of somatostatin receptors.... Agent: Biomeasure, Incorporated

20070299072 - Kv1.5 potassium channel inhibitors: The present invention relates to 4-oxo-1,3,8-triaza-spiro[4.5]decanes which are useful as Kv1.5 potassium channel inhibitors providing atrial-selective antiarrhythmic activity. The present invention further relates to compositions and methods for treating atrial-selective antiarrhythmia.... Agent: Woodcock Washburn LLP/wyeth

20070299074 - Guanidine compounds, and use thereof as binding partners for 5-ht5 receptors: corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of... Agent: Wood, Phillips, Katz, Clark & Mortimer

20070299075 - Novel inhibitors of kinases: and pharmaceutically acceptable salts thereof The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through... Agent: Louis J. Wille Bristol-myers Squibb Company

20070299076 - Substituted 3-amino-pyrrolidino-4-lactams: d

20070299077 - Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament:

20070299078 - Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20070299079 - 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them: The invention relates to 4-amino-pyrido[3,2-e]pyrazines, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10, as active compounds for treating diseases of mammals including a human which can be influenced by using the compounds... Agent: Fulbright & Jaworski, LLP

20070299081 - Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): Formula (I) where x, y, G, J, L, M, V, W, R2, R3, R4, R5, R5a, R6, R6a,... Agent: Seed Intellectual Property Law Group PLLC

20070299082 - Novel azabicyclic aryl derivatives and their medical use: This invention relates to novel azabicyclic aryl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse... Agent: Birch Stewart Kolasch & Birch

20070299080 - Benzamide derivatives and uses related thereto: i

20070299083 - 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts: The present invention relates to hydrochloric acid salt and crystalline forms of the 5-HT1A binding agent 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline, as well as pharmaceutical compositions thereof, and methods of use thereof.... Agent: Fish & Richardson PC

20070299084 - Indole derivatives useful for treating resistance to antitumor agents: The use of a group of indole compounds of formula (I) is described for treating tumours which have developed resistance to antitumour drugs. The compounds of formula (I) can be used in monotherapy, to treat tumours affected by drug resistance, or in co-therapy, as synergistic enhancers of the action of... Agent: Jay S Cinamon Abelman Frayne And Schwab

20070299085 - N1-((pyrazol-1-ymethyl)-2-methylphenyl)-phatalamide derivatives and related compounds insecticides: Novel benzenedicarboxamides of the formula (I) wherein X represents hydrogen, halogen atom, nitro, C1-6alkylsulfonyloxy, C1-6alkylsulfinyl, C1-6alkylsulfenyl or C1-6alkylsulfonyl, R1 represents C1-6alkyl, C1-6alkylthio-C1-6alkyl, or C1-6alkyl, m represents 0 or 1, A represents O, S, SO, SO2, CH2 or CH(CH3), and Q represents a 5- or 6-membered heterocyclic group that contains at... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070299086 - Prolyl hydroxylase inhibitors and methods of use: The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070299087 - New compounds 319: e

20070299088 - Novel uses of 2-phenyl-substituted imidazotriazinone derivatives: The invention relates to the use of PDE 5 inhibitors, and especially of known 2-phenyl-substituted imidazotriazinone derivatives for producing medicaments for the treatment of symptoms that can be treated by increasing cGMP levels in certain tissues, such as acute myocardial infarction and damage caused by reperfusion, various symptoms in the... Agent: Jeffrey M. Greenman

20070299089 - Use of a2a adenosine receptor agonists in the treatment of ischemia: Methods for treating ischemia in mammals with one or more compounds that are agonists of mammalian adenosine A2A receptors.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070299090 - Substituted 8-aminoalkoxy-xanthine compounds and compositions useful in the treatment of hyperlipidemia and diabetes: t

20070299091 - Azaindole carboxamides:

20070299092 - Quinone substituted quinazoline and quinoline kinase inhibitors: The present invention provides for compounds with the general formula: A compound of formula (1) having the structure (1) wherein Z is a radical selected from the group (a), (b), or (c) as well as methods and compositions containing these compounds useful for treatment of diseases that are characterized, at... Agent: Wyeth C/o Darby & Darby, P.C.

20070299094 - 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives: e

20070299093 - Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation: Compounds identified by the general formula (I) are used for the treatment of Alzheimer's disease.... Agent: Marshall, Gerstein & Borun LLP

20070299095 - Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds: The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic... Agent: Rigel Pharmaceuticals Inc.

20070299097 - Strategy for leukemia therapy: The chimeric Bcr-Abl oncoprotein is the molecular hallmark of chronic myelogenous leukemia (CML). In the cytoplasm, the protein transduces a growth signal that is responsible for overexpansion of cells. In the nucleus, the protein induces apoptosis. The invention is a method of treating cancer/killing Bcr-Abl expressing cells by inducing the... Agent: Biotactica, LLC

20070299096 - Treating learning deficits with inhibitors of hmg coa reductase: The disclosure provides methods of treating cognitive disorders by administering a HMG CoA reductase inhibitor. Cognitive deficits treatable with the inhibitor compound include those associated with Angelman Syndrome, Neurofibromatosis-1, certain forms of X-linked mental retardation, tuberous sclerosis, Down Syndrome, autism, and attention deficit/hyperactivity disorder.... Agent: Dorsey & Whitney LLP

20070299098 - Therapeutic agent for neuropathic pain: The present invention provides therapeutic agents for neuropathic pain, the agents having excellent therapeutic effects on neuropathic pain, which is an intractable disorder. More specifically, the invention provides therapeutic agents for neuropathic pain comprising, as the active ingredient, an opioid receptor antagonist (particularly naloxone, naltrexone, naloxonazine, naltrindole, etc.), pharmaceutical compositions... Agent: Foley And Lardner LLP Suite 500

20070299099 - Acid addition salt of irinotecan: The present invention is directed to an irinotecan acid addition salt which is formed through addition of an acid selected from the group consisting of sulfuric acid, nitric acid phosphoric acid, methanesulfonic acid, citric acid maleic acid and succinic acid to Irinotecan, to a method for producing the salt, and... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070299100 - Analgesic: An analgesic which may be applied to wide variety of pain from various causes is disclosed. The analgesic comprises as an effective ingredient a specific morphinan derivative having a nitrogen containing heterocyclic group, such as compound 1:... Agent: Ip Group Of Dla Piper US LLP

20070299101 - Niacin receptor agonists, compositions containing such compounds and methods of treatment: The present invention relates to niacin receptor agonists of formula: (I); as well as pharmaceutically acceptable salts and solvates. The compounds are useful for treating dyslipidemias, and in particular, reducing serum LDL, VLDL and triglycerides, and raising HDL levels. Pharmaceutical compositions and methods of treatment are also included.... Agent: Merck And Co., Inc

20070299102 - Diphenyl ox-indol-2-one compounds and their use in the treatment of cancer: e

20070299103 - [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases: The invention provides novel, substituted 7-arylamino[1,2,4]triazolo[4,3-a]pyridine compounds Formula (I): pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10 R11, R12, R13, R14 and L are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070299104 - Tetrahydropyranyl cyclopentyl 1-substituted and 1,1-disubstituted tetrahydroisoquinoline modulators of chemokine receptor activity: Compounds of Formula I: I (wherein n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, Y and Z are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic... Agent: Merck And Co., Inc

20070299105 - 2-cyanopropanoic acid amide and ester derivatives and methods of their use: m

20070299107 - N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors: The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release NHO at a controlled rate under... Agent: Morrison & Foerster LLP

20070299108 - New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents: e

20070299106 - Novel mycobacterial inhibitors:

20070299109 - Dimeric compounds of piperidine, piperazine or morpholine or their 7-membered analogs suitable for the treatment of neurodegenerative disorders: Formula (I″), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof.... Agent: Philip S. Johnson Johnson & Johnson

20070299110 - Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate: The present invention relates to new tetrazole compounds of formula I wherein B, P, Q, W, R1 and R2 are defined in the description: invention compounds are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.... Agent: Edwards Angell Palmer & Dodge LLP

20070299111 - Benzamide derivatives and uses related thereto: Benzamide derivatives of formula I are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders:... Agent: Foley And Lardner LLP Suite 500

20070299113 - Metabotropic glutamate receptor modulators: The invention relates to imidazothiazole derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR modulators and are therefore useful for the control and prevention of various disorders, including acute... Agent: The Firm Of Hueschen And Sage

20070299112 - Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase i: as inhibitors of human casein kinase Iε and methods for using said compounds for treating central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising compounds of formula (I) or formula (II) and a method for the preparation of compounds of formula (I) or formula... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070299114 - Biaryl derivatives:

20070299115 - (hetero)cyclyl(thio) carboxylic acid anilides for controlling pathogenic fungi: The invention relates to (hetero)cyclyl(thio)carboxylic acid anilides of general formula (I) and to salts of said anilides that can be used for agricultural purposes for controlling pathogenic fungi. In said formula, the variables are defined as follows: A represents a phenyl or at least a monounsaturated 5- or 6-membered heterocycle... Agent: Birch Stewart Kolasch & Birch

20070299116 - Human protein tyrosine phosphatase inhibitors and methods of use: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising one or more human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070299117 - Hydroxypropylaimines: and the pharmaceutically acceptable salts thereof wherein the variables RN, R1, R2, R3, Rp and RC are defined herein. These compounds are useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070299118 - Benzoxazolone derivatives, processes for preparing them and their uses: The present invention relates to benzoxazolone derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, in the treatment of movement disorders, in particular in Parkinson's disease.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070299119 - Prophylactic or therapeutic agent for severe diabetic retinopathy: wherein X represents a halogen or a hydrogen atom, R1 and R2 concurrently or differently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R1 and R2, together with a nitrogen atom bound thereto and optionally another nitrogen atom or an oxygen atom, are combined... Agent: Burr & Brown

20070299120 - Kv1.5 potassium channel inhibitors: The present invention relates to 1-N-amino-2-imidazolidinones and derivatives thereof which are effective as Kv1.5 potassium channel inhibitors providing atrial-selective antiarrhythmic agents. The present invention further relates to compositions comprising said Kv1.5 potassium channel inhibitors, and to methods for treating cardiac arrhythmia.... Agent: Woodcock Washburn LLP/wyeth

20070299121 - Transmucosal veterinary composition comprising detomidine: The present invention relates to a veterinary composition in a semisolid form adapted for transmucosal administration for providing sedation and analgesia in large animals such as horses and cattle. The semisolid transmucosal composition of the invention comprises detomidine or a pharmaceutically acceptable salt thereof as an active ingredient. The composition... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070299123 - Amorphous frovatriptan succinate and process for the preparation thereof: Frovatriptan succinate substantially in an amorphous form is disclosed. Also disclosed is a composition comprising frovatriptan succinate in a solid form, wherein at least about 80% by weight of the solid is frovatriptan succinate in an amorphous form. The present invention also provides a process for preparing frovatriptan succinate substantially... Agent: M. Carmen & Associates, PLLC

20070299122 - Method of treating pathological blushing: A method of treating pathological blushing is disclosed wherein the patient is administered a DP receptor antagonist. Compositions containing DP antagonists are also included.... Agent: Merck And Co., Inc

20070299124 - Formulations and methods for treating dry eye: The present invention provides compositions for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070299125 - Substituted indoles: The present invention relates generally to substituted indoles and methods of using them.... Agent: Woodcock Washburn LLP/wyeth

20070299126 - Substituted pyrrole-indoles: The present invention relates generally to substituted pyrrole-indoles such as substituted pyrrole-indoles, and methods of using them.... Agent: Woodcock Washburn LLP/wyeth

20070299127 - Compositions and kits comprising a melatonin component and an omega-3-fatty acid component: Disclosed herein are compositions and kits, wherein each composition comprises a melatonin component, an omega-3-fatty acid component, or both, and wherein each kit comprises a melatonin component and an omega-3-fatty acid component. The compositions and kits are useful for restorative sleep function and skin benefits. Further disclosed herein are methods... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070299128 - Use of tryptophan derivatives for the specific cytostatic treatment of serotonin-producing tumors: The invention relates to the use of tryptophane-derivatives for the specific cytostatic treatment of serotonin-producing tumors, such as, for example carcinoids and the like. Areas of application of the invention are in the field of medicine and pharmaceutical industry.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070299129 - Compounds and derivatives for the treatment of medical conditions by modulating hormone-sensitive lipase activity: The present invention discloses compounds that are inhibitors of hormone-sensitive lipase. The present invention also discloses the use of the compounds and derivatives to inhibit hormone-sensitive lipase, various pharmaceutical compositions including the compounds, and methods of treatment using these compounds and compositions.... Agent: Marshall, Gerstein & Borun LLP

20070299130 - Benzopyran compound: wherein X is NR6, Y is a bond, SO or SO2, Z is C1-4alkyl group or phenyl group, W is hydrogen atom, hydroxy group, C1-6 alkoxy group, a halogen atom, C1-4alkyl group or C1-6alkylsulfonylamino group, R1 and R2 are independently of each other C1-3alkyl group, R3 is hydrogen atom, hydroxy... Agent: Oliff & Berridge, PLC

20070299131 - Furancarbonylguanidine derivatives, their preparation and pharmaceutical compositions containing them: The present invention relates to furancarbonylguanidine derivatives, a preparation method thereof and a pharmaceutical composition comprising the same. Furancarbonylguanidine derivatives of the present invention inhibit NHE-1 (sodium-hydrogen exchanger isoform 1), which helps recovery of heart function damaged from ischemia/reperfusion and decreases myocardial infarction rate, indicating that they have protective effect... Agent: Lucas & Mercanti, LLP

20070299132 - Stable aqueous formulation of a platin derivative: Disclosed is a stable aqueous formulation of a platin derivative, particularly oxaliplatin. The selected stabilizing additive is effective even in very small concentrations.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070299134 - Concentrated and odorless omega 3 fatty acids: A blend of triglycerides having the general formula CH2(OOC-R1)—CH(OOC—R2)—CH2(OOC—R3), wherein at least about 50% of the R1, R2 and R3 groups have a chain length of C19 or more. The blend of triglycerides has less than about 50 parts per billion (ppb) of trimethyl amine, that is, they are substantially... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070299133 - Concentrated omega-3 fatty acids and mixtures containing them: A stable aqueous emulsion comprising water, a blend of esters including esters of polyunsaturated fatty acids, such as omega-3 fatty acids, emulsifiers and stabilizers is disclosed. The emulsion may be used as a beverage or as an additive that may be added to a beverage or a food product. The... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070299135 - Compositions for use in surgery: A method is provided for treating a subject in need of medication as an adjunct to elective surgery, comprising administration of a ketogenic material sufficient to produce a physiologically acceptable ketosis in the patient. Preferably the surgery is selected from the groups consisting of removal or section of tumours, removal... Agent: Nixon & Vanderhye, PC

20070299136 - Crystalline and amorphous forms of efaproxiral sodium: There are provided in accordance with the present invention crystalline forms A, B, C, F, G, I, J, P, and Q of efaproxiral sodium. Also provided is the amorphous form of efaproxiral sodium. Also provided are methods of forming the novel polymorphs and the amorphous form of efaproxiral sodium, therapeutic... Agent: Swanson & Bratschun, L.L.C.

20070299137 - N-acylated derivatives of dicarboxylic acids with amino acids and vegetable protein hydrolsates and their use in cosmetics and pharmaceuticals: X and Y, which can be the same or different, are OM or a residue of formula MOOCHRNH— wherein R is the residue of a natural alpha-amino acid and M is hydrogen or a non toxic cation, or X and/or Y are a —NH—P residue, wherein P is a polypeptide... Agent: Young & Thompson

20070299138 - St104p, an anti-angiogenic agent: The present invention relates to a method of treating a subject suffering non-tumor condition or disease associated with angiogenesis which comprises administering the subject in need of the treatment with an effective angiogenesis inhibiting dose of a tetrameric cyclic compound of 4,5-dihydroxynaphthalene-2,7, disulfonic acid linked by methylene bridges in a... Agent: Wpat, PC Intellectual Property Attorneys

20070299139 - Lyophilisate comprising n-diaminomethylene-2-methyl-4,5-di(methylsulfonyl)benzamide: The invention relates to a lyophilisate comprising N-diaminomethylene-2-methyl-4,5di(methylsulfonyl)benzamide as active compound. The composition has increased storage stability, even at elevated temperatures, and can be administered parenterally as medicament after reconstitution.... Agent: Millen, White, Zelano & Branigan, P.C.

20070293427 - Hydrolysate of avian cartilage, process of preparation and uses thereof: This invention relates to a hydrolysate of avian cartilage comprising 45% to 70% by weight of hydrolysed type II collagen, 9% to 15% by weight of chondroitin sulphate, 0.5% to 2% in weight of hyaluronic acid; with a composition of amino acids in which valine represents 2.7% to 3.3%, isoleucine... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070293428 - Methods of treating joint pain in a subject by using an anti-angiogenic agent: A method for treating a joint pain in a subject comprising providing an effective amount of an anti-angiogenic agent to a synovial capsule adjacent to the joint.... Agent: Fox Rothschild, LLP

20070293435 - Identification and use of non-peptide analogs of rnaiii-inhibiting peptide for the treatment of staphylococcal infections: RNAIII inhibiting peptide (RIP) has been established as an effective inhibitor of staphylococcal infections. Non-peptide small molecule analogs based on a pharmacophore conforming to the putative atomic structure of RIP, can be identified by computer screening of that pharmacophore against established libraries of known small molecules other than peptides. One... Agent: Jagtiani + Guttag

20070293445 - Stable elsamitrucin salts suitable for pharmaceutical formulations: Stable solid, crystalline forms of elsamitrucin salts are provided that are useful in preparing anti-neoplastic parenteral formulations. Also provided are methods for treating neoplastic diseases in humans using parenteral formulations that include at least one stable elsamitrucin salt.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20070293416 - Ceacam based antibacterial agents: Prophylactic and/or therapeutic antipathogen agents are provided that disrupt or prevent the formation of at least one homotypic and/or heterotypic protein-protein interaction that has at least one CEA-family protein and that is involved in the establishment and colonization of a pathogen in a suitable host.... Agent: Mcandrews Held & Malloy, Ltd

20070293415 - Composition containning flavan compound: A composition comprising: a flavan compound that is at least one of a proanthocyanidin and catechins; a protein degradation peptide having an average molecular weight of less than 7,000; and a peptide or protein having an average molecular weight of not less than 7,000. The composition does not impair effects... Agent: The Webb Law Firm, P.C.

20070293418 - Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis: The invention is directed to a pharmacologically active peptide conjugate having a reduced tendency towards enzymatic cleavage comprising a pharmacologically active peptide sequence (X) and a stabilising peptide sequence (Z) of 4-20 amino acid residues covalently bound to X.... Agent: Clark & Elbing LLP

20070293417 - Polyamides for treating human papilloma virus: The present invention relates to polyamide compositions and therapies for treating cells infected with human papilloma virus (HPV).... Agent: Jonathan P. O'brien Miller, Canfield, Paddock And Stone

20070293421 - Erythropoietin for treatment of multi-organ failure: The compositions and methods disclosed herein are for prevention or treatment of multi-organ failure with erythropoietin. The usefulness of the present invention is that erythropoietin may act to prevent the onset of MOF in a patient at risk of developing it. The present invention may further lessen the effect in... Agent: The Mccallum Law Firm, P. C.

20070293420 - Method for purifying erythropoietin: The invention relates to a method for producing recombined erythropoietin having a particularly high degree of purity (≧98%). The method consists of at least 5 chromatographic purification steps, i.e. at least two anion exchange chromatographs, at least one hydrophobic interaction chromatography, at least one affinity chromatography and at least one... Agent: Knobbe Martens Olson & Bear LLP

20070293419 - Stable, aqueous solution of human erythropoietin, not containing serum albumin: The present invention provides an aqueous formulation of human erythropoietin having the storage stability over a long period without serum albumin, in which the formulation comprises a pharmaceutically effective amount of human erythropoietin; non-ionic surfactant, polyhydric alcohol, neutral amino acid and sugar alcohol as stabilizers; isotonic reagent; and buffering reagent.... Agent: Cantor Colburn, LLP

20070293424 - Antitumoral and antiviral peptides: The invention relates to novel compositions of general formula (1) consisting of X1 Trp Gly Gln X2 or the pharmaceutically acceptable salts or esters or amides thereof, wherein X1 is absent or contains at least one type of aminoacid, X2 is absent or contains at least one type of aminoacid.... Agent: Renner Otto Boisselle & Sklar, LLP

20070293422 - Beta-amyloid inhibitors and use thereof: Peptides and derivatives or analogs thereof are provided for having β-amyloid aggregation inhibitory activity, useful in the treatment and prevention of diseases such as Alzheimer's disease, Dementia pugilistica (including head trauma), Hereditary Cerebral Haemorrhage with amyloidosis of the Dutch type (HCHWA-D) and vascular dementia with amyloid angiopathy.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070293423 - Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (glp)-1 compound or a melanocortin-4 receptor (mc4) agonist peptide: The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.... Agent: Eli Lilly & Company

20070293431 - Method for improving neurotransmission failure using a novel agent: A novel medicament for ameliorating neurotransmission dysfunction diseases is provided. A medicament for ameliorating neurotransmission dysfunction diseases comprising as a main active ingredient preferably a selenocysteine-containing protein such as Selenoprotein P or a selenocysteine-containing peptide that consists of said protein or a series of said peptides. A medicament suited for... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070293426 - Methods for improving islet signaling in diabetes mellitus and for its prevention: The present invention discloses methods for therapeutically treating mammals, including but not limited to humans, to increase the relative insulin producing performance of endogenous pancreatic β-cells, to cause differentiation of pancreatic epithelial cells into insulin producing β-cells, to improve muscle sensitivity to insulin and other weight control efforts by the... Agent: Osi Pharmaceuticals, Inc.

20070293433 - Methods of treating aging of skin with oligosaccharides in cosmetic or dermatological compositions that stimulate adhesion of keratinocytes to major proteins of the dermoepidermal junction and restore epidermal cohesion: A method of treating aging of skin including applying a therapeutically effective amount of an anti-aging dermatological care composition including at least one cosmetic formulation agent and oligogalacturonides having a degree of polymerization between 1 and 5 that stimulates adherence of basal keratinocytes to laminin V and/or collagen IV and... Agent: Ip Group Of Dla Piper US LLP

20070293425 - Mutein of a bone morphogenetic protein and use thereof: The present invention is related to a mutein of a bone morphogenetic protein, whereby the mutein comprises an amino acid substitution compared to the wildtype of the bone morphogenetic protein at the amino acid position corresponding to amino acid position 51 of human BMP-2.... Agent: Fish & NeaveIPGroup Ropes & Gray

20070293430 - Muteins of fibroblast growth factor 21: The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced deamidation compared to wild-type human FGF-21. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the... Agent: Eli Lilly & Company

20070293429 - Vasoactive intestinal polypeptide compositions: Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed.... Agent: Forbes Medi-tech Inc. Attention: Ms. Susan M. Ben-oliel

20070293432 - Vegf antagonist formulations suitable for intravitreal administration: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence shown in SEQ ID NO:4.... Agent: Regeneron Pharmaceuticals, Inc

20070293434 - Binding polypeptides and methods based thereon: Binding polypeptides that specifically bind BLyS protein or BLyS-like polypeptides can be used in methods of the invention for detecting, diagnosing, or prognosing a disease or disorder associated with aberrant BLyS or BLyS receptor expression or inappropriate function of BLyS or BLyS receptor, comprising BLyS binding polypeptides or fragments or... Agent: Leydig, Voit & Mayer Ltd.

20070293436 - Cytoprotective thereapeutic agents for the prevention of reperfusion injury following ischemic stroke: The present invention relates generally to the use of γ-glutamyl antioxidants, particularly γ-glutamyl-cysteine, as cytoprotective agents to prevent reperfusion injury (i.e., hemorrhagic transformation) of the blood-brain barrier during reperfusion following an ischemic stroke. The γ-glutamyl antioxidants can be used alone or used in combination with an agent which inhibits the... Agent: Joseph A. Fuchs Rockey, Depke & Lyons, LLC

20070293438 - Antibody specifically binding to sulfonylated protein protein and method for producing the same: Provided is a method for producing an antibody binding to a sulfonylated isoform of a protein; not to a non-sulfonylated isoform of the protein and other proteins, including: providing a peptide comprised of 6 to 15 amino acids derived from the protein and having a sulfonylated cysteine residue; inducing an... Agent: Lowe Hauptman Ham & Berner, LLP

20070293437 - Expression profiling platform technology: The present invention relates to an efficient mAb panel-based expression profiling technology platform suitable for global and accurate measurement of proteins, peptides and metabolites in complex mixtures. The platform is comprised of new and well established technologies that are coupled in a unique fashion to provide a novel platform technology... Agent: Nixon & Vanderhye, PC

20070293440 - Co-therapy for the treatment of epilepsy and related disorders: The present invention is directed to co-therapy for the treatment of epilepsy and related disorders comprising administering to a subject in need thereof, co-therapy with a therapeutically effective amount of a benzo-fused heterocycle sulfamide derivative and a therapeutically effective amount of one or more anticonvulsant and/or anti-epileptic agents.... Agent: Philip S. Johnson Johnson & Johnson

20070293441 - High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products: The present disclosure provides a sterilized medical system that includes an ultra high pressure sterilized glucose solution in a container. The sterile glucose solution may contain less than about 40 ppm total glucose degradation product. The glucose solution may be a ready-to-use infusion solution disposed in a single chamber container.... Agent: Baxter Healthcare Corporation

20070293439 - Methods and compositions for treating hyperglycemic, hyperlipidemic, or hyperinsulinemic disorders: Methods of treating hyperglycemic, hyperlipidemic, and hyperinsulinemic disorders are provided. Compositions for treating such disorders are also provided. The compositions can include hexose and pentose variants having acid moieties and a substituent Y linked to the six position of a hexose or the five position of the pentose.... Agent: Calfee Halter & Griswold, LLP

20070293442 - Antithrombotic compound: t

20070293443 - Composition for accelerating calcium absorption: The present invention relates to a composition for accelerating calcium absorption containing a poorly absorbable L-form aldonic acid, a salt thereof, or a poorly absorbable L-form aldonolactone. The invention also relates to a food or beverage containing L-arabonic acid, a salt thereof, or L-arabonolactone. The invention also relates to a... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070293446 - Compositions comprising c-13 alkoxyether macrolide compounds and phenylpyrazole compounds: e

20070293444 - Novel nucleoside transport inhibitors: Compounds or compositions that are inhibitors and/or ligands of nucleoside transporters; and methods of treating cancer, heart disease and stroke, as well as AIDS and other infectious diseases... Agent: John K. Buolamwini

20070293452 - Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial: The present invention provides agents which are capable of regulating the function of a micro-RNA component which can be used to regulate an ACHE-associated biological pathway. In addition, the present invention provides methods and pharmaceutical compositions for the treatment of various pathologies related to AChE-associated biological pathways such as apoptosis,... Agent: Martin D. Moynihan Prtsi, Inc.

20070293453 - Combinatorial methods for inducing cancer cell death: The present invention relates to methods and compositions for inhibiting proliferation and inducing cell death in a population of cancer cells by (i) increasing the amount of the differentiation associated protein MDA-7, and (ii) decreasing RAS activity within the population. It is based, at least in part, on the discovery... Agent: Baker Botts L.L.P.

20070293449 - Compositions and methods for delivery of double-stranded rna: Pharmaceutical compositions and methods of use of a composition containing a double-stranded RNA (dsRNA), cationic lipids, non-cationic lipids, and lipophilic delivery-enhancing compounds.... Agent: Nastech Pharmaceutical Company Inc

20070293447 - Gene therapy for skin disorders using needleless syringes: The present invention provides highly useful clinical methods for treating skin disorders, particularly intractable skin disorders. Specifically, the methods comprise injecting/subcutaneously introducing a 10 μg to 10 mg dose of a polynucleotide, such as a DNA, oligonucleotide, RNA, siRNA, and antisense, around a lesion associated with a skin disorder, such... Agent: Townsend And Townsend And Crew, LLP

20070293450 - Identification of ses-3 and the uses of same: The invention relates to isolated nucleic acid molecules coding for SES-3 proteins or muted SES-3 proteins, and vectors and transgenic organisms containing such nucleic acid molecules. The invention also relates to uses of such nucleic acid molecules or others which are functionally similar, for producing pharmaceuticals and for producing model... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070293451 - Regulation ao apob by hsp110 proteins and related compositions and methods: Hsp110 proteins are shown herein to stabilize nascent ApoB protein. Methods of down-regulating expression of ApoB, and thus down-regulating serum cholesterol levels, are therefore, provided, including, without limitation, inhibition of Hsp110 expression by any method, for example and without limitation, by RNA interference (RNAi). It also has been found that... Agent: Jesse A. Hirshman, Esq.

20070293448 - Synthetic gagpol genes and their uses: The present invention relates to synthetic gag and gagpol genes optimized for high level expression via codon optimization and the uses thereof for the efficient generation of vector particles. The invention further relates to the generation of packaging cells and vaccines based on the synthetic gag and gagpol genes.... Agent: Fulbright & Jaworski L.L.P.

20070293454 - Complex containing mequitazine, a cyclodextrin and an interaction agent: The present invention relates to a complex that includes mequitazine, a cyclodextrin, and an interaction agent wherein the rate of solubilization in water of complexed mequitazine, measured for a 2 g/l mixture of mequitazine in water at 35° C. after 15 minutes of stirring, is greater than 50% at pH... Agent: Birch Stewart Kolasch & Birch

20070293456 - Method for the synthesis of 3-substituted indolizine and benzoindolizine compounds: e

20070293455 - Silylated carboxamides:

20070293457 - Boron-containing small molecules as anti-inflammatory agents: Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.... Agent: Morgan, Lewis & Bockius LLP (sf)

20070293458 - Prevention of nuclear, solar, and other radiation-induced tissue damage: Inositol hexaphosphate (IP-6) is a polyphosphorylated carbohydrate with potent antioxidant activity to prevent active oxygen species-mediated mutagenesis, cell injury and carcinogenesis. IP-6 also activates DNA repair mechanisms. Sublethal radiation causes DNA damage through the formation of free radicals, reactive oxygen species, and pyrimidine crosslinks leading to cellular proliferation, cell cycle... Agent: Bingham Mccutchen LLP

20070293459 - Method for inhibiting cellular na+-k+ atpase activity: The present invention discloses an inhibitive effect of Na+—K+-ATPase caused by a compound selected from the group consisting of magnesium lithospermate B (MLB), isomer, prodrug, derivative, pharmaceutically acceptable salt, and a composition thereof. In this invention, the variations of Na+—K+-ATPase activity were monitored with increasing MLB concentrations, and the result... Agent: Pai Patent & Trademark Law Firm

20070293461 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, d, m, n, p, r, R1, R2, R3, R4, R5, R6, R7, and W are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and... Agent: Theravance, Inc.

20070293460 - Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease: A method of delivery of a combination therapy to the pulmonary system that includes providing a nebulizer and an aqueous solution comprising a long-acting corticosteroid, a long-acting beta-agonist, and a long-acting anticholinergic, and administering the solution to the patient using the nebulizer. The corticosteroid is budesonide, the beta-agonist is formoterol... Agent: Akerman Senterfitt

20070293462 - Method for inhibiting cellular na+-k+ atpase activity: The present invention discloses an inhibitive effect of Na+-K+-ATPase caused by a compound selected from the group consisting of magnesium lithospermate B (MLB), isomer, prodrug, derivative, pharmaceutically acceptable salt, and a composition thereof. In this invention, the variations of Na+-K+-ATPase activity were monitored with increasing MLB concentrations, and the result... Agent: Pai Patent & Trademark Law Firm

20070293463 - Method for shortening hospital stay in patients with congestive heart failure and acute fluid overload: Methods of treating patients with acute fluid overload comprising administering diuretic therapy and an amount of KW-3902, a pharmaceutically acceptable salt, ester, amide, metabolite, or prodrug thereof, effective to accelerate removal of excess fluid from the patient in comparison to diuretic therapy alone. Methods of improving the treatment time to... Agent: Knobbe Martens Olson & Bear LLP

20070293464 - Substituted pyrimidine compositions and methods of use: Novel compositions and methods of using substituted pyrimidines which have the general formula: (I)... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20070293465 - Compounds for enzyme inhibition: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering... Agent: Ropes & Gray LLP Patent Docketing 39/41

20070293466 - Antimicrobial chelates: Methods useful for inhibiting growth of a variety of microbes including bacteria and fungi are disclosed. The meth